The clinical impact of non-obstructive chronic bronchitis in current and former smokers
Carlos H Martinez, Victor Kim, Yahong Chen, Ella A Kazerooni, Susan Murray, Gerard J Criner, Jeffrey L Curtis, Elizabeth A Regan, Emily Wan, Craig P Hersh, Edwin K Silverman, James D Crapo, Fernando J Martinez, Meilan K Han, COPDGene Investigators, Carlos H Martinez, Victor Kim, Yahong Chen, Ella A Kazerooni, Susan Murray, Gerard J Criner, Jeffrey L Curtis, Elizabeth A Regan, Emily Wan, Craig P Hersh, Edwin K Silverman, James D Crapo, Fernando J Martinez, Meilan K Han, COPDGene Investigators
Abstract
Background: As the clinical significance of chronic bronchitis among smokers without airflow obstruction is unclear, we sought to determine morbidity associated with this disorder.
Methods: We examined subjects from the COPDGene study and compared those with FEV1/FVC ≥ 0.70, no diagnosis of asthma and chronic bronchitis as defined as a history of cough and phlegm production for ≥ 3 months/year for ≥ 2 years (NCB) to non-obstructed subjects without chronic bronchitis (CB-). Multivariate analysis was used to determine factors associated with and impact of NCB.
Results: We identified 597 NCB and 4283 CB- subjects. NCB participants were younger (55.4 vs. 57.2 years, p < 0.001) with greater tobacco exposure (42.9 vs. 37.8 pack-years, p < 0.001) and more often current smokers; more frequently reported occupational exposure to fumes (52.8% vs. 42.2%, p < 0.001), dust for ≥ 1 year (55.3% vs. 42.0%, p < 0.001) and were less likely to be currently working. NCB subjects demonstrated worse quality-of-life (SGRQ 35.6 vs. 15.1, p < 0.001) and exercise capacity (walk distance 415 vs. 449 m, p < 0.001) and more frequently reported respiratory "flare-ups" requiring treatment with antibiotics or steroids (0.30 vs. 0.10 annual events/subject, p < 0.001) prior to enrollment and during follow-up (0.34 vs. 0.16 annual events/subject, p < 0.001). In multivariate analysis, current smoking, GERD, sleep apnea and occupational exposures were significantly associated with NCB.
Conclusions: While longitudinal data will be needed to determine whether NCB progresses to COPD, NCB patients have poorer quality-of-life, exercise capacity and frequent respiratory events. Beyond smoking cessation interventions, further research is warranted to determine the benefit of other therapeutics in this population. Clinical Trials Registration # NCT00608764 (https://ichgcp.net/clinical-trials-registry/NCT00608764). Link to study protocol: http://www.copdgene.org/sites/default/files/COPDGeneProtocol-5-0_06-19-2009.pdf.
Keywords: Cough; GERD; Gastroesophageal reflux; Occupational exposure; Quality of life; Tobacco.
Copyright © 2013 Elsevier Ltd. All rights reserved.
Source: PubMed